Company Announcement no. 19/2008 To: OMX Nordic Exchange Copenhagen Hørsholm, Denmark, April 17, 2008 LifeCycle Pharma A/S - Report Pursuant to the Danish Securities Trading Act, Section 28(a) Hørsholm, Denmark, April 17, 2008; Pursuant to the Danish Securities Trading Act, Section 28(a), LifeCycle Pharma A/S (OMX: LCP) is required on a daily basis, to make public transactions in LifeCycle Pharma shares and related securities by persons discharging managerial responsibilities and persons / companies closely associated with these. Name Dr. Thomas Dyrberg Reason for reporting Member of the Board of Directors Issuer and ID code/ISIN LifeCycle Pharma A/S / DK0060131043 Type of transaction Purchase of shares Date of transaction April 15, 2008 Relevant market OMX Nordic Exchange Copenhagen Number of traded securities 6,600 Market value DKK 112,200 Name Dr. Michael Beckert Reason for reporting Chief Medical Officer & EVP Issuer and ID code/ISIN LifeCycle Pharma A/S / DK0060131043 Type of transaction Purchase of shares Date of transaction April 15, 2008 Relevant market OMX Nordic Exchange Copenhagen Number of traded securities 20,000 Market value DKK 340,000 Name Peter G. Nielsen Reason for reporting EVP Pharmaceutical Development and CMC Issuer and ID code/ISIN LifeCycle Pharma A/S / DK0060131043 Type of transaction Purchase of shares Date of transaction April 15, 2008 Relevant market OMX Nordic Exchange Copenhagen Number of traded securities 1,000 Market value DKK 17,000 About LifeCycle Pharma A/S (“LCP”) LCP is an emerging specialty pharmaceutical company that, through innovative technologies, is able to rapidly develop a portfolio of differentiated products to meet the unique needs of key therapeutic markets and patient populations. This includes products for immunosuppression, specifically organ transplantation, and to combat certain cardiovascular diseases. By using its unique and patented delivery technology, MeltDose®, LCP is able to develop drugs with enhanced absorption and thereby increased bioavailability. LCP has a cholesterol lowering product, FenoglideTM, currently on the U.S. market and a diversified near- and medium-term pipeline, including five product candidates in clinical trials and three in preclinical stages of development. LCP is listed on the OMX Nordic Exchange Copenhagen under the trading symbol (OMX: LCP). For further information, please visit www.lcpharma.com. Contact: LifeCycle Pharma A/S Hans Christian Teisen EVP and CFO +45 2030 6985 HCT@lcpharma.com
LifeCycle Pharma A/S - Report Pursuant to the Danish Securities Trading Act, Section 28(a)
| Source: Veloxis Pharmaceuticals A/S
Attachments
